CRC mortality | All-cause mortality | |||||
---|---|---|---|---|---|---|
N event/N Total | HR | (95% CI) | N event/N Total | HR | (95% CI) | |
Colorectal cancer | ||||||
Quintile 1 | 91/248 | 1 | Reference | 112/248 | 1 | Reference |
Quintile 2 | 89/245 | 0.98 | (0.71, 1.34) | 114/245 | 0.94 | (0.71, 1.24) |
Quintile 3 | 87/249 | 0.80 | (0.58, 1.10) | 116/249 | 0.79 | (0.60, 1.05) |
Quintile 4 | 94/247 | 0.85 | (0.62, 1.17) | 124/247 | 0.84 | (0.64, 1.11) |
Quintile 5 | 94/246 | 0.92 | (0.66, 1.28) | 124/246 | 0.91 | (0.68, 1.21) |
p-trend | 0.76 | 0.76 | ||||
per doubling in CRP | 0.95 | (0.89, 1.01) | 0.96 | (0.91, 1.01) | ||
Colorectal cancer, men only | ||||||
Quintile 1 | 39/117 | 1 | Reference | 53/117 | 1 | Reference |
Quintile 2 | 48/134 | 1.00 | (0.64, 1.57) | 65/134 | 0.93 | (0.63, 1.36) |
Quintile 3 | 52/136 | 0.87 | (0.55, 1.37) | 67/136 | 0.76 | (0.51, 1.13) |
Quintile 4 | 45/114 | 1.00 | (0.62, 1.60) | 63/114 | 0.94 | (0.63, 1.41) |
Quintile 5 | 42/108 | 0.99 | (0.60, 1.61) | 58/108 | 0.89 | (0.58, 1.34) |
p-trend | 0.94 | 0.86 | ||||
per doubling in CRP | 0.98 | (0.90, 1.08) | 0.97 | (0.89, 1.05) | ||
Colorectal cancer, women only | ||||||
Quintile 1 | 52/131 | 1 | Reference | 59/131 | 1 | Reference |
Quintile 2 | 41/111 | 1.00 | (0.62, 1.60) | 49/111 | 0.98 | (0.64, 1.50) |
Quintile 3 | 35/113 | 0.74 | (0.45, 1.21) | 49/113 | 0.88 | (0.57, 1.36) |
Quintile 4 | 49/133 | 0.71 | (0.45, 1.13) | 61/133 | 0.74 | (0.49, 1.12) |
Quintile 5 | 52/138 | 0.77 | (0.47, 1.25) | 66/138 | 0.90 | (0.59, 1.39) |
p-trend | 0.32 | 0.68 | ||||
per doubling in CRP | 0.91 | (0.83, 1.00) | 0.94 | (0.87, 1.02) | ||
p-interaction by sex | 0.18 | 0.31 | ||||
Colon cancer | ||||||
Quintile 1 | 57/152 | 1 | Reference | 71/152 | 1 | Reference |
Quintile 2 | 45/139 | 0.88 | (0.57, 1.36) | 59/139 | 0.82 | (0.56, 1.19) |
Quintile 3 | 54/148 | 0.83 | (0.54, 1.25) | 75/148 | 0.80 | (0.56, 1.15) |
Quintile 4 | 63/160 | 0.78 | (0.51, 1.17) | 84/160 | 0.71 | (0.50, 1.02) |
Quintile 5 | 74/181 | 0.94 | (0.63, 1.41) | 92/181 | 0.83 | (0.58, 1.18) |
p-trend | 0.89 | 0.61 | ||||
per doubling in CRP | 0.95 | (0.88, 1.03) | 0.93 | (0.86, 0.99) | ||
Colon cancer, men only | ||||||
Quintile 1 | 21/67 | 1 | Reference | 31/67 | 1 | Reference |
Quintile 2 | 24/69 | 1.26 | (0.64, 2.48) | 33/69 | 1.02 | (0.59, 1.77) |
Quintile 3 | 29/77 | 0.92 | (0.48, 1.76) | 40/77 | 0.69 | (0.40, 1.19) |
Quintile 4 | 27/71 | 0.98 | (0.50, 1.93) | 39/71 | 0.79 | (0.45, 1.37) |
Quintile 5 | 30/77 | 1.00 | (0.51, 1.96) | 40/77 | 0.74 | (0.42, 1.30) |
p-trend | 0.80 | 0.35 | ||||
per doubling in CRP | 0.98 | (0.86, 1.11) | 0.92 | (0.82, 1.02) | ||
Colon cancer, women only | ||||||
Quintile 1 | 36/85 | 1 | Reference | 40/85 | 1 | Reference |
Quintile 2 | 21/70 | 0.62 | (0.33, 1.18) | 26/70 | 0.65 | (0.37, 1.15) |
Quintile 3 | 25/71 | 0.83 | (0.44, 1.56) | 35/71 | 0.99 | (0.57, 1.70) |
Quintile 4 | 36/89 | 0.60 | (0.33, 1.09) | 45/89 | 0.61 | (0.36, 1.04) |
Quintile 5 | 44/104 | 0.69 | (0.38, 1.24) | 52/104 | 0.80 | (0.48, 1.35) |
p-trend | 0.48 | 0.74 | ||||
per doubling in CRP | 0.88 | (0.78, 0.99) | 0.91 | (0.82, 1.00) | ||
p-interaction by sex in colon cancer | 0.39 | 0.60 | ||||
Rectal cancer | ||||||
Quintile 1 | 34/96 | 1 | Reference | 41/96 | 1 | Reference |
Quintile 2 | 44/106 | 1.05 | (0.62, 1.76) | 55/106 | 0.98 | (0.62, 1.56) |
Quintile 3 | 33/101 | 0.77 | (0.45, 1.32) | 41/101 | 0.78 | (0.48, 1.26) |
Quintile 4 | 31/87 | 0.89 | (0.50, 1.58) | 40/87 | 0.94 | (0.57, 1.54) |
Quintile 5 | 20/65 | 0.86 | (0.44, 1.70) | 32/65 | 1.18 | (0.68, 2.07) |
p-trend | 0.59 | 0.45 | ||||
per doubling in CRP | 0.93 | (0.83, 1.05) | 1.01 | (0.91, 1.12) | ||
p-interaction by location | 0.61 | 0.41 | ||||
Rectal cancer, men only | ||||||
Quintile 1 | 22/50 | 1 | Reference | 22/50 | 1 | Reference |
Quintile 2 | 32/65 | 1.18 | (0.57, 2.43) | 32/65 | 1.16 | (0.62, 2.16) |
Quintile 3 | 27/59 | 1.06 | (0.49, 2.27) | 27/59 | 0.93 | (0.47, 1.81) |
Quintile 4 | 24/43 | 1.02 | (0.44, 2.36) | 24/43 | 1.34 | (0.66, 2.75) |
Quintile 5 | 18/31 | 1.19 | (0.46, 3.05) | 18/31 | 1.51 | (0.70, 3.27) |
p-trend | 0.87 | 0.25 | ||||
per doubling in CRP | 0.97 | (0.82, 1.15) | 1.06 | (0.92, 1.22) | ||
p-interaction by location in men | 0.59 | 0.06 | ||||
Rectal cancer, women only | ||||||
Quintile 1 | 16/46 | 1 | Reference | 19/46 | 1 | Reference |
Quintile 2 | 20/41 | 1.05 | (0.42, 2.63) | 23/41 | 1.05 | (0.48, 2.32) |
Quintile 3 | 10/42 | 0.40 | (0.14, 1.11) | 14/42 | 0.47 | (0.19, 1.15) |
Quintile 4 | 13/44 | 0.60 | (0.23, 1.57) | 16/44 | 0.62 | (0.27, 1.42) |
Quintile 5 | 8/34 | 0.41 | (0.13, 1.30) | 14/34 | 0.75 | (0.29, 1.95) |
p-trend | 0.12 | 0.47 | ||||
per doubling in CRP | 0.85 | (0.69, 1.03) | 0.90 | (0.76, 1.07) | ||
p-interaction by location in women | 0.41 | 0.64 | ||||
p-interaction by sex in rectal cancer | 0.13 | 0.27 | ||||
Stage I or II | ||||||
Quintile 1 | 33/131 | 1 | Reference | 38/131 | 1 | Reference |
Quintile 2 | 16/107 | 0.62 | (0.33, 1.18) | 25/107 | 0.73 | (0.43, 1.24) |
Quintile 3 | 23/115 | 0.70 | (0.39, 1.25) | 33/115 | 0.75 | (0.45, 1.24) |
Quintile 4 | 14/100 | 0.58 | (0.29, 1.16) | 26/100 | 0.72 | (0.42, 1.26) |
Quintile 5 | 25/111 | 0.82 | (0.44, 1.55) | 42/111 | 0.98 | (0.58, 1.67) |
p-trend | 0.97 | 0.52 | ||||
per doubling in CRP | 0.92 | (0.82, 1.04) | 0.97 | (0.87, 1.07) | ||
Stage III or IV | ||||||
Quintile 1 | 52/81 | 1 | Reference | 60/81 | 1 | Reference |
Quintile 2 | 60/99 | 0.76 | (0.51, 1.15) | 71/99 | 0.76 | (0.52, 1.10) |
Quintile 3 | 57/103 | 0.72 | (0.47, 1.09) | 71/103 | 0.70 | (0.48, 1.03) |
Quintile 4 | 67/119 | 0.73 | (0.49, 1.09) | 81/119 | 0.68 | (0.47, 0.99) |
Quintile 5 | 62/113 | 0.72 | (0.47, 1.11) | 72/113 | 0.71 | (0.48, 1.05) |
p-trend | 0.36 | 0.27 | ||||
per doubling in CRP | 0.93 | (0.86, 1.01) | 0.93 | (0.86, 1.00) | ||
p-interaction by stage | 0.91 | 0.19 |